CBDG — THC Farmaceuticals Share Price
Last trade - 00:00- $0.27m
- $0.18m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.1 | ||
| Price to Tang. Book | 0.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 0.02 | 0.01 | 0 | 0.01 | n/a | n/a | -20.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
THC Farmaceuticals, Inc. is a clinical-stage biotechnology company. The Company specializes in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology and other medical disciplines. It offers the combination of its proprietary developments with its clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds. The Company owns clinical research center and cannabidiol (CBD) manufacturing facility in California. Its business plan includes conducting cannabinoids research and development in collaboration with cannabis research centers worldwide with the goal of developing novel and advanced therapeutic methods for the treatment of common medical conditions with cannabis-based therapies and to conduct pre-clinical investigations and randomized, placebo-controlled trials of CBD-based compounds and develop condition-specific medications. It offers a network of micro vending kiosk systems.
Directors
- Last Annual
- September 30th, 2022
- Last Interim
- September 30th, 2020
- Incorporated
- April 14th, 2005
- Public Since
- August 22nd, 2012
- No. of Employees
- 2
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 16,631,600
- Address
- 7170 E McDonald Dr Ste 3, SCOTTSDALE, 85253-5424
- Web
- Phone
- +1 4807259060
- Auditors
- John Scrudato CPA
Upcoming Events for CBDG
Similar to CBDG
American Green
Pink Sheets on Nasdaq
Bit Brother
Pink Sheets on Nasdaq
Blue Gem Enterprise
Pink Sheets on Nasdaq
Blum Holdings
Pink Sheets on Nasdaq
Can B
Pink Sheets on Nasdaq
FAQ
As of Today at 19:21 UTC, shares in THC Farmaceuticals are trading at $0.02. This share price information is delayed by 15 minutes.
Shares in THC Farmaceuticals last closed at $0.02 and the price had moved by +1241.67% over the past 365 days. In terms of relative price strength the THC Farmaceuticals share price has outperformed the S&P500 Index by +1083.71% over the past year.
There is no consensus recommendation for this security.
THC Farmaceuticals does not currently pay a dividend.
THC Farmaceuticals does not currently pay a dividend.
THC Farmaceuticals does not currently pay a dividend.
To buy shares in THC Farmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.02, shares in THC Farmaceuticals had a market capitalisation of $0.27m.
Here are the trading details for THC Farmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CBDG
Based on an overall assessment of its quality, value and momentum THC Farmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like THC Farmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +38.79%.
As of the last closing price of $0.02, shares in THC Farmaceuticals were trading -82.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The THC Farmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
THC Farmaceuticals' management team is headed by:
- Ed Rosenthal - PRE
- Eric Miller - DRC